The companies Vaxcyte, Generate Biomedicines, and Immunic bagged the biggest biotech funding rounds overall in February 2026.

With fresh billions unlocked in the 2026 U.S. budget and mission‑driven family offices recalibrating after a “nuclear winter, ...

A reversal of cuts to the National Institutes of Health budget has life sciences operators breathing a sigh of relief.

Tomorrow BioTech and Green2Gold unite to support biotech and green innovators with labs, mentorship, and a path to ...

As funding constraints and shifting investment priorities reshape the CGT landscape, the importance of building resilient, collaborative frameworks is evident.

Slate Medicines, a new Raleigh biotechnology company developing treatments for migraine and headache disorders, has announced ...

"We are also seeing improvement in US biotech funding, as well as higher M&A and IPO activity, which are leading indicators ...

Raleigh-based Slate Medicines just pulled in a hefty $130 million Series A, a war chest the startup says will fuel development of SLTE‑1009, an in‑licensed anti‑PACAP monoclonal antibody aimed at ...

The AI drug discovery specialist is the fifth biotechnology company to go public in February and priced the sector’s largest ...

Just as a disciplined a soccer player might pass on a hopeful shot in favor of a better chance later on, the biopharma venture capital market reflected a preference for de-risked assts over platforms ...

At first glance, the European Commission’s Biotech Act proposal may appear as another sectoral initiative aimed at boosting innovation. On closer reading, however, it signals something far more ...